At median 45.3 months follow up, atezolizumab significantly improved DFS vs. best supportive care after resection and adjuvant chemotherapy in PD-L1 tumor cell (TC) ≥ 1% and OS benefit with atezolizumab vs. best supportive care being strongest in the PD-L1 ≥ 50% in stage II–IIIA HR = 0.43 (95% CI: 0.24–0.78). Here, CD274 is linked to neoplasm.